Abstract:Modern-day hematopoietic stem cell (HSC) therapies, such as gene therapy, modify autologous HSCs prior to re-infusion into myelo-conditioned patients and hold great promise for treatment of hematological disorders. While this approach has been successful in numerous clinical trials, it relies on transplantation of ex vivo modified patient HSCs, which presents several limitations. It is a costly and time-consuming procedure, which includes only few patients so far, and ex vivo culturing negatively impacts on the viability and stem cell-properties of HSCs. If viral vectors are used, this carries the additional risk of insertional mutagenesis. A therapy delivered to HSCs in vivo, with minimal disturbance of the HSC niche, could offer great opportunities for novel treatments that aim to reverse disease symptoms for hematopoietic disorders and could bring safe, effective and affordable genetic therapies to all parts of the world. However, substantial unmet needs exist with respect to the in vivo delivery of therapeutics to HSCs. In the last decade, in particular with the development of gene editing technologies such as CRISPR/Cas9, nanoparticles (NPs) have become an emerging platform to facilitate the manipulation of cells and organs. By employing surface modification strategies, different types of NPs can be designed to target specific tissues and cell types in vivo. HSCs are particularly difficult to target due to the lack of unique cell surface markers that can be utilized for cell-specific delivery of therapeutics, and their shielded localization in the bone marrow (BM). Recent advances in NP technology and genetic engineering have resulted in the development of advanced nanocarriers that can deliver therapeutics and imaging agents to hematopoietic stem- and progenitor cells (HSPCs) in the BM niche. In this review we provide a comprehensive overview of NP-based approaches targeting HSPCs to control and monitor HSPC activity in vitro and in vivo, and we discuss the potential of NPs for the treatment of malignant and non-malignant hematological disorders, with a specific focus on the delivery of gene editing tools.

[Development of hematopoietic stem cell-targeted gene therapy]

Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned

Therapy Development by Genome Editing of Hematopoietic Stem Cells

Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders

Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease

Gene therapy using haematopoietic stem and progenitor cells

Advancements in Hematopoietic Stem Cell Gene Therapy: A Journey of Progress for Viral Transduction

In vivo hematopoietic stem cell modification by mRNA delivery

Development and clinical translation of ex vivo gene therapy

In Vivo Hematopoietic Stem Cell Transduction

Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy

In vivo genome editing of human hematopoietic stem cells for treatment of blood disorders by mRNA delivery

Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements

Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells

Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation

Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects

In Vivo Selection for Gene-Corrected HSPCs Advances Gene Therapy for a Rare Stem Cell Disease

Hematopoietic stem cell collection for sickle cell disease gene therapy

A simplified, G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model.

Nanoparticles targeting hematopoietic stem and progenitor cells: Multimodal carriers for the treatment of hematological diseases

Gene therapy and gene editing strategies in inherited blood disorders